Kymera Therapeutics Inc KYMR

US Biotechnology

$103.40 ▼ -3.37% ($-3.61)

⬇️ Below Yest. Low 🗓️ Earnings Next Week

Open $106.25

Prev Close $107.01

Day Range $102.13 – $106.73

52W Range $36.65 – $130.05

Market Cap $8.51B

Beta 1.95

EPS (TTM) $-3.57

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-08-21
Shares Out.	82,260,000
Website	kymeratx.com/ ↗
Phone	13026587581
Employees	253
Revenue	$34.4M
Gross Profit	$34.4M
Net Income	-$69.2M
Free Cash Flow	-$244.0M
Total Assets	$1.67B
Total Liabilities	$129.4M
Equity	$1.54B

About Kymera Therapeutics Inc

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Kymera Therapeutics Inc is a publicly traded company under the ticker symbol KYMR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.